Clinical studies

/ph/metabolic/empagliflozin/cv-risk-protection/emprise-rwe-updates-ada-2020

EMPRISE RWE updates from ADA 2020
/ph/metabolic/empagliflozin/efficacy/how-slow-down-progression-kidney-disease

How to slow down the progression of Kidney Disease
/ph/metabolic/empagliflozin-linagliptin/safety/cardiovascular-renal-safety

Cardiovascular & Renal Safety
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-data

Linagliptin Efficacy Data
/ph/metabolic/empagliflozin-linagliptin/efficacy/2020-american-association-clinical-endocrinology

2020 American Association of Clinical Endocrinology Guidelines
/ph/metabolic/empagliflozin-linagliptin/efficacy/multiple-benefits-one-small-pill

Multiple Benefits in one small pill
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-vs-other-dpp4i-fue

Linagliptin Efficacy vs Other DPP4i FUE
/ph/metabolic/linagliptin/cv-renal-safety/trajenta-cvot-infographic

Trajenta CVOT infographic
/ph/metabolic/empagliflozin/guidelines/phmore-80-guidelines-worldwide-endorse-empagliflozin

PH_MORE THAN 80 GUIDELINES WORLDWIDE ENDORSE EMPAGLIFLOZIN (JARDIANCE)_Infographic
/ph/respiratory/spiolto/efficacy/spiolto-respimat-inhaleability-infographic-092020

Spiolto Respimat Inhaleability Infographic 092020
/ph/metabolic/linagliptin/efficacy/emperor-reduced-results-fuecardios

EMPEROR-Reduced RESULTS FUE_Cardios
/ph/metabolic/empagliflozin/efficacy/empagliflozin-jardiance-reduced-risk-hospitalisation-heart

Empagliflozin (Jardiance ) reduced the risk in hospitalisation for heart failure
/ph/cardiovascular/dabigatran-etexilate/safety/ph-re-dual-vs-augustus-infographic

PH_RE-DUAL_vs_AUGUSTUS_infographic
/ph/cardiovascular/dabigatran-etexilate/reversibility/praxbind-numbers-infographic-flashcard

Praxbind by the Numbers Infographic Flashcard
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozins-early-impact-cv-death-reduction

Empagliflozin's early impact in CV Death Reduction
/ph/metabolic/empagliflozin/cv-risk-protection/t2d-cvd-risk-equivalent

T2D is a CVD risk equivalent
/ph/metabolic/empagliflozin/efficacy/jardiance-gives-you-power-accomplish-more-providing-multiple

Jardiance gives you the power to accomplish more by providing multiple benefits
/ph/metabolic/linagliptin/cv-renal-safety/cv-and-kidney-safety-linagliptin-ina-asians-adc

CV and Kidney Safety of Linagliptin ina Asians ADC
/ph/metabolic/linagliptin/efficacy/linagliptin-efficacy-vs-other-dpp4i-adc

Linagliptin Efficacy vs Other DPP4i ADC
/ph/metabolic/linagliptin/cv-renal-safety/carolina-asian-subanalysis

Carolina Asian Subanalysis
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-near-us-insights-its-use-asians

Empagliflozin near to us: Insights from its use in Asians
/ph/metabolic/empagliflozin/cv-risk-protection/empagliflozin-clinical-endorsement-revolutionising

Empagliflozin's clinical endorsement: Revolutionising guidelines across specialties
/ph/metabolic/linagliptin/cv-renal-safety/carmelina-asian-subanalysis

CARMELINA Asian Subanalysis
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empagliflozin-cv-indication-wave-change-across

Empagliflozin CV indication : A wave of change across the world
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empa-reg-outcome-breakthrough-trial-type-2

EMPA-REG OUTCOME: A Breakthrough trial in Type 2 Diabetes
/ph/respiratory/spiolto/respimat/thank-you-all-who-participated-2019-respeedmat-challenge

Thank you to all who participated in the 2019 ReSpeedMat Challenge!
/ph/metabolic/empagliflozin/guidelines/t2d-cvd-risk-equivalent

T2D is a CVD risk equivalent
/ph/metabolic/empagliflozin/guidelines/2019-esc-guidelines

2019 ESC Guidelines
/ph/metabolic/linagliptin/efficacy/linagliptin-dependable-efficacy

Linagliptin: Dependable efficacy in type 2 diabetes
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-forum-2018-dr-mansoor-husain

Asian CardioDiabetes Forum 2018 - The role of a cardiologist in diabetes management - Dr. Mansoor Husain (transcript)
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-forum-2018-dr-neale-cohen

Asian CardioDiabetes Forum 2018 - How have recent CV outcome trials influence clinical practice by Dr. Neale Cohen (transcript)
/ph/metabolic/empagliflozin/experts-interview/asian-cardiodiabetes-forum-2018-prof-richard-donnelly

Asian CardioDiabetes Forum 2018 - Why is it important to examine evidence and not assume class effect by Prof. Richard Donnelly (transcript)
/ph/metabolic/empagliflozin/cv-risk-protection/emprise-empagliflozin-real-world-effectiveness

EMPRISE - Empagliflozin Real World Effectiveness
/ph/respiratory/spiolto/prescribing-information

Tiotropium + olodaterol (Spiolto® Respimat®) Prescribing Information
/ph/oncology/giotrif/safety/realgido-real-world-study

RealGiDo - Real-world study on dose adjustment
/ph/oncology/giotrif/sequencing/giotag-real-world-study

GioTag: Real-world study on Afatinib (Giotrif®) followed by osimertinib in EGFR m+ NSCLC patients
/ph/oncology/giotrif/efficacy/singapore-real-world-data

Singapore Real World Data
/ph/oncology/giotrif/efficacy/south-korea-real-world-data

South Korea Real World Data
/ph/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information
/ph/cardiovascular/dabigatran-etexilate/safety/low-dose-noac-usage-closer-look

Low-Dose NOAC Usage: A Closer Look
/ph/metabolic/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duo

Empagliflozin Metformin HCI (Jardiance Duo®) Prescribing Information
/ph/metabolic/linagliptin/prescribing-information/linagliptin-metformin-hcl-trajenta-duo-prescribing

Linagliptin Metformin HCl (Trajenta Duo®) Prescribing Information
/ph/metabolic/linagliptin/prescribing-information/linagliptin-trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/ph/metabolic/jardiance-empagliflozin/empa-reg-outcome-trial/randomised-controlled-trials-vs-real-world

Randomised Controlled Trials vs Real World Evidence
/ph/cardiovascular/dabigatran-etexilate/prescribing-information/idarucizumab-praxbind-prescribing

Idarucizumab (Praxbind®) Prescribing Information
/ph/cardiovascular/dabigatran-etexilate/prescribing-information/dabigatran-etexilate-prescribing

Dabigatran etexilate (Pradaxa®) Prescribing information
/ph/metabolic/empagliflozin/empa-reg-outcome-trial/empa-reg-outcome-study-result

EMPA-REG Outcome study result
Load more